PMID- 29412697
OWN - NLM
STAT- MEDLINE
DCOM- 20180822
LR  - 20211204
IS  - 1557-8852 (Electronic)
IS  - 1084-9785 (Linking)
VI  - 33
IP  - 1
DP  - 2018 Feb
TI  - miR-155 Affects Osteosarcoma MG-63 Cell Autophagy Induced by Adriamycin Through 
      Regulating PTEN-PI3K/AKT/mTOR Signaling Pathway.
PG  - 32-38
LID - 10.1089/cbr.2017.2306 [doi]
AB  - OBJECTIVE: Phosphatase and tensin homolog deleted on chromosome 10 (PTEN) plays a 
      positive regulatory role on cell autophagy through inhibiting PI3K/AKT/mammalian 
      target of rapamycin (mTOR) signaling pathway. miR-155 plays a critical role in 
      osteosarcoma occurrence and chemoresistance. Bioinformatics analysis revealed the 
      targeted binding site between miR-155 and the 3'-UTR (untranslated region) of 
      PTEN mRNA. This study investigated the role of miR-155 in regulating osteosarcoma 
      cell autophagy, chemosensitivity to Adriamycin (ADM), and PTEN-PI3K/AKT/mTOR 
      signaling pathway. MATERIALS AND METHODS: Dual luciferase reporter gene assay 
      confirmed the relationship between miR-155 and PTEN. MG-63 cells and 
      drug-resistant MG-63/ADM cells were treated by ADM to compare miR-155, PTEN, 
      p-AKT, p-mTOR, and Beclin-1 expressions. Cell apoptosis was tested by flow 
      cytometry. MG-63/ADM cells were divided into five groups, including anti-miR-NC, 
      anti-miR-155, pSicoR-blank, pSicoR-PTEN, and anti-miR-155+pSicoR-PTEN group. 
      RESULTS: miR-155 targeted suppressed PTEN expression. miR-155, p-AKT, and p-mTOR 
      significantly increased, while PTEN and Beclin-1 obviously reduced in MG-63/ADM 
      cells compared with MG-63 cells. ADM treatment markedly elevated miR-155, p-AKT, 
      and p-mTOR expressions, whereas reduced PTEN level. Beclin-1 was slightly 
      upregulated, and autophagy and apoptosis levels were low. Anti-miR-155 and/or 
      pSicoR-PTEN significantly enhanced PTEN and Beclin-1 expressions, cell apoptosis, 
      and autophagy induced by ADM and declined p-AKT and p-mTOR levels. CONCLUSIONS: 
      miR-155 targeted suppressed PTEN expression, enhanced PI3K/AKT/mTOR signaling 
      pathway, inhibited cell apoptosis and autophagy induced by ADM, and reduced 
      sensitivity to ADM.
FAU - Wang, Lin
AU  - Wang L
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
FAU - Tang, Bing
AU  - Tang B
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
FAU - Han, Heng
AU  - Han H
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
FAU - Mao, Dan
AU  - Mao D
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
FAU - Chen, Jie
AU  - Chen J
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
FAU - Zeng, Yun
AU  - Zeng Y
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
FAU - Xiong, Min
AU  - Xiong M
AD  - Department of Orthopedics Institute, Affiliated Dongfeng Hospital, Hubei 
      University of Medicine , Shiyan, China .
LA  - eng
PT  - Journal Article
PT  - Retracted Publication
DEP - 20180207
PL  - United States
TA  - Cancer Biother Radiopharm
JT  - Cancer biotherapy & radiopharmaceuticals
JID - 9605408
RN  - 0 (MIRN155 microRNA, human)
RN  - 0 (MicroRNAs)
RN  - 0 (Phosphoinositide-3 Kinase Inhibitors)
RN  - 80168379AG (Doxorubicin)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (Proto-Oncogene Proteins c-akt)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 3.1.3.67 (PTEN Phosphohydrolase)
RN  - EC 3.1.3.67 (PTEN protein, human)
SB  - IM
RIN - Cancer Biother Radiopharm. 2021 Sep;36(7):614. PMID: 34357784
MH  - Autophagy/drug effects/genetics
MH  - Bone Neoplasms/drug therapy/genetics/metabolism/pathology
MH  - Doxorubicin/*pharmacology
MH  - Humans
MH  - MicroRNAs/*metabolism
MH  - Osteosarcoma/drug therapy/genetics/metabolism/pathology
MH  - PTEN Phosphohydrolase/*metabolism
MH  - Phosphatidylinositol 3-Kinases/metabolism
MH  - Phosphoinositide-3 Kinase Inhibitors
MH  - Proto-Oncogene Proteins c-akt/*metabolism
MH  - Signal Transduction/drug effects
MH  - TOR Serine-Threonine Kinases/*metabolism
OTO - NOTNLM
OT  - PTEN-PI3K/AKT/mTOR
OT  - autophagy
OT  - miR-155
OT  - osteosarcoma
EDAT- 2018/02/08 06:00
MHDA- 2018/08/23 06:00
CRDT- 2018/02/08 06:00
PHST- 2018/02/08 06:00 [pubmed]
PHST- 2018/08/23 06:00 [medline]
PHST- 2018/02/08 06:00 [entrez]
AID - 10.1089/cbr.2017.2306 [doi]
PST - ppublish
SO  - Cancer Biother Radiopharm. 2018 Feb;33(1):32-38. doi: 10.1089/cbr.2017.2306. Epub 
      2018 Feb 7.